2023 was a banner year for Team Rhaeos where we kicked off the first quarter with a Series A close and closed the last quarter with the completion of our 9 center FDA pivotal study. Here are some highlights of the year:
💰Series A close of $10.5M ✅. The round was led by the Steele Foundarion for Hope with follow on investments from Creative Ventures and Lateral Capital.
💰Non-dilutive funding ✅ We received a BP MedTech and diversity grants from the NIH. We also received funding from the Southwest Pediatric Device Consortium and the West Coast Consortium for Technology and Innovations. Funds total >$1.6M.
🏥 FDA pivotal study ✅. We completed a 9 center study in the US - coast to coast from UCSF to Duke. We are thankful for our collaborators across the country!
🔬FlowSense home device study cohort #1 ✅. We kicked off our clinical study to bring our remote wearable home!
🏥 5 Clinical studies ✅. CLINICAL EVIDENCE MATTERS! Rhaeos completed 5 clinical studies this year, adding significant data to our portfolio of products.
🥼Chief Medical Officer ✅. Internationally renowned hydrocephalus researcher and neurosurgeon, Dave Limbrick, Jr. MD, PhD joined us as our CMO!
🌎Conferences ✅. We exhibited at major national and international neurosurgery, hydrocephalus, and digital health conferences including CNS, AANS, Hydrocephalus 2023, HLTH, and more!
🧍♀️🧍♂️Team Expansion ✅. We added 13 employees and consultants to the team.
🇬🇧 International Accelerator ✅. We were selected to participate in the Cedars-Sinai/NHS/KHP Ventures Accelerator in London.
What’s in store for 2024? A LOT. Keep following us for more.